Sickle cell gene therapies offer new hope, but access remains a major challenge
FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.
